These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8306243

  • 1. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
    DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I, Shen S, Renn O, Meares CF.
    Cancer; 1994 Feb 01; 73(3 Suppl):1012-22. PubMed ID: 8306243
    [Abstract] [Full Text] [Related]

  • 2. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.
    J Nucl Med; 1997 Aug 01; 38(8):1180-5. PubMed ID: 9255145
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL.
    Anticancer Res; 2000 Aug 01; 20(5C):3647-55. PubMed ID: 11268433
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
    Thomas GE, Esteban JM, Raubitschek A, Wong JY.
    Int J Radiat Oncol Biol Phys; 1995 Feb 01; 31(3):529-34. PubMed ID: 7852116
    [Abstract] [Full Text] [Related]

  • 7. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul 01; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 8. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.
    Cancer; 1997 Dec 15; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 15; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL.
    Cancer Biother Radiopharm; 1998 Oct 01; 13(5):351-61. PubMed ID: 10851425
    [Abstract] [Full Text] [Related]

  • 15. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, Brechbiel MW, Gansow OA, Top LE, Perentesis P, Reynolds JC, Nelson DL, Waldmann TA.
    J Nucl Med; 1999 Feb 01; 40(2):268-76. PubMed ID: 10025834
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
    Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn SD, Butchko G.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5921s-5924s. PubMed ID: 7493371
    [Abstract] [Full Text] [Related]

  • 18. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 19. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.
    Harrison A, Walker CA, Parker D, Jankowski KJ, Cox JP, Craig AS, Sansom JM, Beeley NR, Boyce RA, Chaplin L.
    Int J Rad Appl Instrum B; 1991 Oct 01; 18(5):469-76. PubMed ID: 1917516
    [Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs.
    Quadri SM, Shao Y, Blum JE, Leichner PK, Williams JR, Vriesendorp HM.
    Nucl Med Biol; 1993 Jul 01; 20(5):559-70. PubMed ID: 8358341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.